U.S. Markets closed

Elan announces publication of EGM Circular in respect of proposed demerger

Elan announced the publication and filing of a circular to shareholders convening an extraordinary general meeting, or EGM, to be held in the Davenport Hotel, 8/10 Merrion Street Lower, Dublin 2, Ireland at 10.00 a.m. on Dec. 12, at which a resolution in connection with the proposed demerger of Elan’s Neotope business -- now referred to as the Prothena Business -- originally announced on Aug. 13,, will be considered and voted on. As previously announced, and assuming the necessary preconditions are fulfilled, including an affirmative vote of the Elan shareholders at the EGM, the Prothena business which comprises a substantial portion of Elan’s drug discovery business platform, will be separated into another company by way of a demerger. This company, previously named Neotope Corp.oration plc, but now named Prothena Corp. plc, will be a new publicly traded company incorporated in Ireland.